Preventing Adverse Patient Responses to Cancer Chemotherapeutics
Abstract
The purpose of this project is to prevent adverse patient responses to the cancer drug irinotecan by analyzing the gut microbiomes of patients. The scope of this project is to study irinotecan metabolism and the microbiome over time using fecal samples from healthy individuals and metastatic colorectal cancer patients. In this final report, we describe our accomplishments and the impact of our progress. Briefly, we have 1) developed novel tools to aid in the discovery of connections between the microbiome and patient phenotypes such as drug metabolism; 2) we have revealed novel chemical-chemical interactions in the gut that are relevant to drug metabolism; 3) we have for the first time characterized temporal colorectal cancer patient microbiomes during treatment with therapeutic strategies that include the drug irinotecan and are beginning to unravel specific microbiome interactions with adverse patient responses to irinotecan. In total, our research has contributed substantially to the fields understanding of gut microbiome/disease/metabolic interactions in metastatic colorectal cancer patients. Regarding the products resulting from this funding we published an additional three original research papers this year which acknowledged DoD funding, bringing the total number of publications this grant has supported to 15.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1201591
Entities
People
- Libusha Kelly
Organizations
- Albert Einstein College of Medicine